论文部分内容阅读
目的:探讨紫杉醇联合顺铂新辅助化疗在早中期宫颈癌治疗中的临床应用效果。方法:选取60例早中期宫颈癌患者,按照随机数字表法将其分为观察组和对照组,每组各30例,对照组单纯行宫颈癌根治术,观察组在行宫颈癌根治术前给予紫杉醇联合顺铂新辅助化疗,比较两组的近期疗效、不良反应发生情况及术后病理检查结果。结果:观察组与对照组临床有效率分别为56.7%、33.3%,组间差异明显,具有统计学意义(P<0.05)。两组不良反应发生率、术后宫旁累及率和淋巴结阳性率无明显差异,差异无统计学意义(P>0.05)。结论:紫杉醇联合顺铂新辅助化疗可提高早中期宫颈癌治疗的临床效果,且不会增加不良反应的发生,值得推广应用。
Objective: To investigate the clinical effect of neoadjuvant chemotherapy combined with paclitaxel and cisplatin in the treatment of early-stage cervical cancer. Methods: Sixty patients with early-stage cervical cancer were selected and divided into observation group and control group according to random number table. Each group had 30 cases. The control group was treated with radical mastectomy only. Before the operation, Paclitaxel combined with cisplatin neoadjuvant chemotherapy, the two groups of short-term efficacy, adverse reactions and postoperative pathological examination results. Results: The clinical effective rates of the observation group and the control group were 56.7% and 33.3%, respectively, with significant difference between the two groups (P <0.05). There was no significant difference in the incidence of adverse reactions, paravaginal lymph node metastasis and lymph node positive rate between the two groups (P> 0.05). Conclusion: Paclitaxel combined with cisplatin neoadjuvant chemotherapy can improve the clinical efficacy of early and mid-term cervical cancer treatment, and does not increase the incidence of adverse reactions, it is worth promoting the application.